228 related articles for article (PubMed ID: 19479148)
1. Efficiency and safety of etanercept after acute hepatitis induced by infliximab for psoriasis.
Kluger N; Girard C; Guillot B; Bessis D
Acta Derm Venereol; 2009; 89(3):332-4. PubMed ID: 19479148
[No Abstract] [Full Text] [Related]
2. Psoriasis options abound. Ongoing research on Enbrel and Raptiva supports their use in psoriasis treatment.
Krueger GG
Health News; 2004 Jan; 10(1):10-1. PubMed ID: 15002383
[No Abstract] [Full Text] [Related]
3. [A case of granulomatous rosacea coinciding with the use of etanercept: no relapse with infliximab].
Winter UM; Treudler R; Paasch U; Sticherling M; Simon JC
Hautarzt; 2008 Sep; 59(9):724-7. PubMed ID: 18465064
[TBL] [Abstract][Full Text] [Related]
4. [Biologics in the treatment of psoriasis].
Dissemond J; Grabbe S
MMW Fortschr Med; 2006 Sep; 148(38):42-4. PubMed ID: 17036963
[TBL] [Abstract][Full Text] [Related]
5. Biologic therapy for psoriasis--the first wave: infliximab, etanercept, efalizumab, and alefacept.
Weinberg JM; Saini R; Tutrone WD
J Drugs Dermatol; 2002 Dec; 1(3):303-10. PubMed ID: 12851990
[TBL] [Abstract][Full Text] [Related]
6. Biologicals in the treatment of psoriasis.
Boker A; Kimball AB; Rolz-Cruz G
Curr Opin Investig Drugs; 2007 Nov; 8(11):939-46. PubMed ID: 17979028
[TBL] [Abstract][Full Text] [Related]
7. Experience with biologics for psoriasis in daily practice: switching is worth a try.
Lecluse LL; de Groot M; Bos JD; Spuls PI
Br J Dermatol; 2009 Oct; 161(4):948-51. PubMed ID: 19663876
[No Abstract] [Full Text] [Related]
8. Tolerability and safety of biological therapies for psoriasis in daily clinical practice: a study of 103 Italian patients.
Brunasso AM; Puntoni M; Salvini C; Delfino C; Curcic P; Gulia A; Massone C
Acta Derm Venereol; 2011 Jan; 91(1):44-9. PubMed ID: 21088813
[TBL] [Abstract][Full Text] [Related]
9. Hepatitis: a rare, but important, complication of infliximab therapy for psoriasis.
Wahie S; Alexandroff A; Reynolds NJ
Clin Exp Dermatol; 2006 May; 31(3):460-1. PubMed ID: 16681606
[No Abstract] [Full Text] [Related]
10. Treatment of psoriatic arthritis and recalcitrant skin disease with combination therapy.
Hamilton TK
J Drugs Dermatol; 2008 Nov; 7(11):1089-93. PubMed ID: 19110745
[TBL] [Abstract][Full Text] [Related]
11. Antipsoriatic biologic agents for the treatment of atopic dermatitis.
Heymann WR
J Am Acad Dermatol; 2007 May; 56(5):854-5. PubMed ID: 17437891
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of tumor necrosis factor inhibitors in acute generalized pustular psoriasis.
Viguier M; Aubin F; Delaporte E; Pagès C; Paul C; Beylot-Barry M; Goujon C; Rybojad M; Bachelez H;
Arch Dermatol; 2012 Dec; 148(12):1423-5. PubMed ID: 23247492
[No Abstract] [Full Text] [Related]
13. [TNF alpha in the physiopathology of psoriasis].
Rozieres A; Hennino A; Nicolas JF
Ann Dermatol Venereol; 2006 Feb; 133(2):174-80. PubMed ID: 16508606
[No Abstract] [Full Text] [Related]
14. Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials.
Brimhall AK; King LN; Licciardone JC; Jacobe H; Menter A
Br J Dermatol; 2008 Aug; 159(2):274-85. PubMed ID: 18547300
[TBL] [Abstract][Full Text] [Related]
15. Infliximab-induced hepatitis: absence of cross-toxicity with etanercept.
Thiéfin G; Morelet A; Heurgué A; Diebold MD; Eschard JP
Joint Bone Spine; 2008 Dec; 75(6):737-9. PubMed ID: 18693125
[TBL] [Abstract][Full Text] [Related]
16. [Adverse reactions during biological therapy for psoriasis: results of a survey of the Spanish Psoriasis Group].
Sánchez-Regaña M; Dilmé E; Puig L; Bordas X; Carrascosa JM; Ferran M; Herranz P; García-Bustinduy M; López Estebaranz JL; Alsina M; Rodríguez MA; Ribera M; Fernández-López E; Moreno JC; Belinchón Romero I; Vidal D;
Actas Dermosifiliogr; 2010 Mar; 101(2):156-63. PubMed ID: 20223158
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of etanercept in patients with psoriasis and hepatitis C.
Ventura F; Gomes J; Duarte Mda L; Fernandes JC; Brito C
Eur J Dermatol; 2010; 20(6):808-9. PubMed ID: 20923749
[No Abstract] [Full Text] [Related]
18. Severe generalized exanthema due to etanercept given for severe plaque psoriasis.
Gonzalo-Garijo MA; Pérez-Calderón R; de Argila Fernández-Durán D
Ann Allergy Asthma Immunol; 2008 Jun; 100(6):621-2. PubMed ID: 18592833
[No Abstract] [Full Text] [Related]
19. Efficacy of etanercept in psoriatic patients previously treated with infliximab.
Pitarch G; Sánchez-Carazo JL; Mahiques L; Oliver V
Dermatology; 2008; 216(4):312-6. PubMed ID: 18230978
[TBL] [Abstract][Full Text] [Related]
20. [New systemic treatments for psoriasis: etanercept, infliximab, adalimumab, efalizumab and alefacept].
Bos WE; Thio HB; Neumann HA; van der Fits L; Prens EP
Ned Tijdschr Geneeskd; 2006 May; 150(19):1065-70. PubMed ID: 16733982
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
